ResMed to Acquire Noctrix Health for $340M

Why It Matters

The acquisition gives ResMed a foothold in the fast‑growing neuromodulation segment and addresses an underserved RLS market, strengthening revenue diversification and potential margin expansion.

Key Takeaways

• ResMed to buy Noctrix Health for $340 million, closing June 1 2026.
• Nidra™ TOMAC device offers drug‑free therapy for refractory RLS.
• Acquisition adds ~ $24 million annual revenue and higher gross margins.
• Expected EPS dilution of $0.02, but long‑term margin expansion.
• Integration taps ResMed’s AirView platform for remote adherence monitoring.

Pulse Analysis

The sleep‑medicine landscape is evolving from a narrow focus on obstructive sleep apnea to a broader, neurologically‑driven model that tackles disorders such as restless‑legs syndrome (RLS). Affecting roughly 7 % of adults worldwide, RLS remains largely untreated because existing pharmacologic options carry risks of augmentation and long‑term side effects. ResMed’s $340 million purchase of Noctrix Health signals a strategic pivot toward high‑margin, device‑based therapies that can capture this unmet demand. By bringing the FDA‑cleared Nidra™ TOMAC system into its portfolio, ResMed positions itself at the intersection of neurology and digital sleep health.

The Nidra™ system differentiates itself through tonic motor activation, delivering high‑frequency stimulation to the peroneal nerve to suppress the urge to move without systemic drug exposure. Clinical evidence from the RESTFUL program shows responder rates above 70 % and an average 11‑point reduction in IRLS scores, while safety data reveal only mild skin irritation. A U.S. cost‑effectiveness analysis estimates an incremental cost‑effectiveness ratio of $38 k per QALY, well under the $50 k benchmark, making it attractive to Medicare and private insurers. The device’s $7,500 price point, coupled with $75 monthly supplies, fits within existing CMS reimbursement codes (E0743).

Beyond the product itself, ResMed can accelerate adoption by embedding Nidra™ into its AirView tele‑monitoring suite and myAir patient app, offering clinicians real‑time adherence data similar to CPAP therapy. The company’s extensive home‑medical‑equipment network and recent VirtuOx acquisition provide an end‑to‑end pathway—from at‑home diagnosis to integrated treatment and outcomes tracking. This vertical integration not only diversifies revenue away from the saturated CPAP market but also creates a defensible moat against competitors. If ResMed successfully scales the RLS platform and expands TOMAC to related neurologic conditions, the neuromodulation segment could become a multi‑billion‑dollar growth engine by 2030.

Deal Summary

ResMed announced a definitive agreement to acquire Noctrix Health, the maker of the Nidra™ TOMAC system, for approximately $340 million. The transaction, expected to close around June 1 2026, expands ResMed’s portfolio into neuromodulation for restless‑legs syndrome and strengthens its digital sleep‑health platform. The deal underscores ResMed’s strategy to broaden beyond CPAP devices into high‑margin, non‑pharmacological therapies.